GM Advisory Group LLC raised its holdings in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 35.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,899 shares of the company’s stock after purchasing an additional 500 shares during the quarter. GM Advisory Group LLC’s holdings in Zoetis were worth $371,000 at the end of the most recent reporting period.
Several other hedge funds have also added to or reduced their stakes in ZTS. Cetera Investment Advisers grew its position in shares of Zoetis by 275.2% in the first quarter. Cetera Investment Advisers now owns 96,085 shares of the company’s stock valued at $16,259,000 after purchasing an additional 70,476 shares during the last quarter. Simplify Asset Management Inc. acquired a new position in Zoetis in the 3rd quarter valued at $11,684,000. Soltis Investment Advisors LLC bought a new position in Zoetis during the 1st quarter worth $688,000. Bank Pictet & Cie Asia Ltd. increased its position in Zoetis by 41.0% during the 2nd quarter. Bank Pictet & Cie Asia Ltd. now owns 37,500 shares of the company’s stock worth $6,501,000 after buying an additional 10,900 shares during the period. Finally, Swedbank AB lifted its holdings in shares of Zoetis by 56.2% during the second quarter. Swedbank AB now owns 1,946,277 shares of the company’s stock worth $337,407,000 after buying an additional 700,398 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on the stock. Piper Sandler upped their price target on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Stifel Nicolaus increased their target price on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. increased their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Finally, BTIG Research lifted their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $221.44.
Zoetis Trading Up 0.2 %
Shares of ZTS opened at $176.98 on Friday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The firm has a market cap of $79.85 billion, a price-to-earnings ratio of 33.27, a PEG ratio of 2.71 and a beta of 0.90. The business’s fifty day moving average is $185.62 and its 200-day moving average is $180.53.
Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.46 by $0.12. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. Zoetis’s revenue was up 11.6% compared to the same quarter last year. During the same period last year, the firm posted $1.36 earnings per share. Equities analysts anticipate that Zoetis Inc. will post 5.9 EPS for the current fiscal year.
Zoetis Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio is 32.52%.
Zoetis Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Recommended Stories
- Five stocks we like better than Zoetis
- How Investors Can Find the Best Cheap Dividend Stocks
- Tesla Investors Continue to Profit From the Trump Trade
- How to Evaluate a Stock Before Buying
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- 3 Best Fintech Stocks for a Portfolio Boost
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.